Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C7H7NO2.C6H14N4O2 |
| Molecular Weight | 311.3369 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=CC=C(C=C1)C(O)=O.N[C@@H](CCCNC(N)=N)C(O)=O
InChI
InChIKey=QYWIRGMTYYEDBZ-VWMHFEHESA-N
InChI=1S/C7H7NO2.C6H14N4O2/c8-6-3-1-5(2-4-6)7(9)10;7-4(5(11)12)2-1-3-10-6(8)9/h1-4H,8H2,(H,9,10);4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t;4-/m.0/s1
| Molecular Formula | C6H14N4O2 |
| Molecular Weight | 174.201 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C7H7NO2 |
| Molecular Weight | 137.136 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
L-arginine is a nonessential amino acid that may play an important role in the treatment of cardiovascular disease due to its antiatherogenic, anti-ischemic, antiplatelet, and antithrombotic properties. It has been promoted as a growth stimulant and as a treatment for erectile dysfunction in men. L-arginine is a nonessential amino acid that may play an important role in the treatment of heart disease due to its block arterial plaque buildup, blood clots, platelet clumping, and to increase blood flow through the coronary artery. L-arginine is commonly sold as a health supplement claiming to improve vascular health and treat erectile dysfunction in men. L-arginine, which is promoted as a human growth stimulant, has also been used in bodybuilding. In the 1800s, it was first isolated from animal horn.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q5T6X5 Gene ID: 222545.0 Gene Symbol: GPRC6A Target Organism: Homo sapiens (Human) |
44.1 µM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
| Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
| Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
| Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
| Preventing | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
310 μM |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
6219 μM |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
882 μM |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
24788 M × min |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
265435 M × min |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
38223 M × min |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
77.5 min |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
41.6 min |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
59.6 min |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
100% EXPERIMENT https://www.jci.org/articles/view/103568 |
ARGININE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Disc. AE: Cardiopulmonary arrest, Metabolic acidosis... AEs leading to discontinuation/dose reduction: Cardiopulmonary arrest Sources: Page: p.621Metabolic acidosis (acute) Hyponatremia (severe) |
200 mg/kg 3 times / day multiple, oral Highest studied dose Dose: 200 mg/kg, 3 times / day Route: oral Route: multiple Dose: 200 mg/kg, 3 times / day Sources: Page: p.63 |
unhealthy, 24 n = 11 Health Status: unhealthy Condition: Cystic fibrosis Age Group: 24 Sex: M+F Population Size: 11 Sources: Page: p.63 |
|
15 g 2 times / day multiple, oral Studied dose Dose: 15 g, 2 times / day Route: oral Route: multiple Dose: 15 g, 2 times / day Sources: Page: p.1 |
healthy, 34 ± 2.6 n = 12 Health Status: healthy Condition: Dietary supplementation Age Group: 34 ± 2.6 Sex: M+F Population Size: 12 Sources: Page: p.1 |
|
7 g 3 times / day multiple, oral Studied dose Dose: 7 g, 3 times / day Route: oral Route: multiple Dose: 7 g, 3 times / day Sources: Page: p.200 |
unhealthy, 43± 16 n = 10 Health Status: unhealthy Condition: Hypercholesterolaemia Age Group: 43± 16 Sex: M+F Population Size: 10 Sources: Page: p.200 |
DLT: Gastrointestinal discomfort... Dose limiting toxicities: Gastrointestinal discomfort (20%) Sources: Page: p.200 |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cardiopulmonary arrest | Disc. AE | 3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
| Metabolic acidosis | acute Disc. AE |
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
| Hyponatremia | severe Disc. AE |
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
| Gastrointestinal discomfort | 20% DLT |
7 g 3 times / day multiple, oral Studied dose Dose: 7 g, 3 times / day Route: oral Route: multiple Dose: 7 g, 3 times / day Sources: Page: p.200 |
unhealthy, 43± 16 n = 10 Health Status: unhealthy Condition: Hypercholesterolaemia Age Group: 43± 16 Sex: M+F Population Size: 10 Sources: Page: p.200 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Two novel mutations (Y141H; C214Y) and previously published mutation (R142W) in the RDS-peripherin gene in autosomal dominant macular dystrophies in Spanish families. | 2001 |
|
| A rare case of complete human erythrocyte AMP deaminase deficiency due to two novel missense mutations in AMPD3. | 2001 |
|
| Novel mutations in the GALK1 gene in patients with galactokinase deficiency. | 2001 |
|
| Optimization of experimental conditions for RNA-based sequencing of MLH1 and MSH2 genes. | 2001 |
|
| Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. | 2001 |
|
| Renal response during acute unilateral ureteral obstruction in rats. | 2001 |
|
| The dialytic failure of the peritoneal membrane. | 2001 |
|
| Hemodialysis techniques and advanced glycation end products. | 2001 |
|
| AGE in micro- and macroangiopathy. | 2001 |
|
| Signal-binding specificity of the mu4 subunit of the adaptor protein complex AP-4. | 2001 Apr 20 |
|
| An intrahelical salt bridge within the trigger site stabilizes the GCN4 leucine zipper. | 2001 Apr 27 |
|
| Fructose-6-phosphate aldolase is a novel class I aldolase from Escherichia coli and is related to a novel group of bacterial transaldolases. | 2001 Apr 6 |
|
| Amino acid residues outside of the pore region contribute to N-type calcium channel permeation. | 2001 Feb 23 |
|
| The nutritional management of urea cycle disorders. | 2001 Jan |
|
| Current strategies for the management of neonatal urea cycle disorders. | 2001 Jan |
|
| Prevention of diabetes for up to 13 years by autoislet transplantation after pancreatectomy for chronic pancreatitis. | 2001 Jan |
|
| Biglycan, a vascular proteoglycan, binds differently to HDL2 and HDL3: role of apoE. | 2001 Jan |
|
| Fibroblast growth factor-2 stimulates endothelial nitric oxide synthase expression and inhibits apoptosis by a nitric oxide-dependent pathway in Nb2 lymphoma cells. | 2001 Jan |
|
| Differential effects of glucagon-like peptide-1 (7-36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro. | 2001 Jan |
|
| Effect of AVT antisense oligodeoxynucleotides on AVT release induced by hypertonic stimulation in chicks. | 2001 Jan |
|
| Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. | 2001 Jan |
|
| How the Pseudomonas aeruginosa ExoS toxin downregulates Rac. | 2001 Jan |
|
| Regulation of potassium channel Kir 1.1 (ROMK) abundance in the thick ascending limb of Henle's loop. | 2001 Jan |
|
| Alteration of humoral and peripheral vascular responses during graded exercise in heart failure. | 2001 Jan |
|
| Agmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme. | 2001 Jan |
|
| [Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS. | 2001 Jan |
|
| An extended hydrophobic interactive surface of Yersinia pestis Caf1M chaperone is essential for subunit binding and F1 capsule assembly. | 2001 Jan |
|
| Increased colocalization of corticotropin-releasing factor and arginine vasopressin in paraventricular neurones of the hypothalamus in lactating rats: evidence from immunotargeted lesions and immunohistochemistry. | 2001 Jan |
|
| A metabolic fragment of bradykinin, Arg-Pro-Pro-Gly-Phe, protects against the deleterious effects of lipopolysaccharide in rats. | 2001 Jan |
|
| Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension. | 2001 Jan |
|
| Relationship between flow rate and NO production in postnatal mesenteric arteries. | 2001 Jan |
|
| Altered TNF-alpha, glucose, insulin, and amino acids in islets of Langerhans cultured in a microgravity model system. | 2001 Jan |
|
| Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70. | 2001 Jan 1 |
|
| Tec kinase signaling in T cells is regulated by phosphatidylinositol 3-kinase and the Tec pleckstrin homology domain. | 2001 Jan 1 |
|
| Substitution of Asp114 or Arg116 in the fingers domain of moloney murine leukemia virus reverse transcriptase affects interactions with the template-primer resulting in decreased processivity. | 2001 Jan 12 |
|
| Glutamine metabolism to glucosamine is necessary for glutamine inhibition of endothelial nitric oxide synthesis. | 2001 Jan 15 |
|
| Amino acid residues in ribonuclease MC1 from bitter gourd seeds which are essential for uridine specificity. | 2001 Jan 16 |
|
| Structure and organization of bacteriophage Pf3 probed by Raman and ultraviolet resonance Raman spectroscopy. | 2001 Jan 16 |
|
| Insights into the molecular basis for the carbenicillinase activity of PSE-4 beta-lactamase from crystallographic and kinetic studies. | 2001 Jan 16 |
|
| Strain is more important than electrostatic interaction in controlling the pKa of the catalytic group in aspartate aminotransferase. | 2001 Jan 16 |
|
| Upregulation of the nitric oxide-cGMP pathway in aged myocardium: physiological response to l-arginine. | 2001 Jan 19 |
|
| Exercise training in coronary artery disease and coronary vasomotion. | 2001 Jan 2 |
|
| Site-specific single amino acid changes to Lys or Arg in the central region of the movement protein of a hybrid bromovirus are required for adaptation to a nonhost. | 2001 Jan 5 |
|
| Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. | 2001 Jan 5 |
|
| The role of nitric oxide in bradycardia of rats with obstructive cholestasis. | 2001 Jan 5 |
|
| C60-Fullerene monomalonate adducts selectively inactivate neuronal nitric oxide synthase by uncoupling the formation of reactive oxygen intermediates from nitric oxide production. | 2001 Jan 9 |
|
| Acetaldehyde, a metabolite of ethanol, activates the hypothalamic-pituitary-adrenal axis in the rat. | 2001 Jan-Feb |
|
| Effect of oxygen on induction of the cystine transporter by bacterial lipopolysaccharide in mouse peritoneal macrophages. | 2001 Mar 30 |
|
| Scanning mutagenesis reveals roles for helix n of the bacteriophage T7 RNA polymerase thumb subdomain in transcription complex stability, pausing, and termination. | 2001 Mar 30 |
|
| Rare somatic p53 mutation identified in breast cancer: a case report. | 2001 Mar-Apr |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: I.V route is possible: The recommended adult dose is 30 g arginine hydrochloride (300 mL of R-Gene 10) administered by intravenous infusion over 30 minutes. The total dose should not exceed 30 g arginine hydrochloride.
https://www.drugs.com/dosage/r-gene-10.html
L-arginine has been studied at oral doses of 6 to 30 g/day for a variety of conditions. Many formulations have been used.
Route of Administration:
Oral
A strong inward current in X. laevis oocytes expressing 5.24 (C terminus of the homologous goldfish 5.24 receptor) when L-Arg (L-arginine) was applied at 10 uM. When testing chimera h6A/5.24 (h6A/5.24, containing the ligand binding amino-terminal domain (ATD) of hGPRC6A with the signal transducing transmembrane and C terminus of the homologous goldfish 5.24 receptor) in this system, the responses were obtained with L-Arg at 100 uM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 02:06:53 GMT 2023
by
admin
on
Sat Dec 16 02:06:53 GMT 2023
|
| Record UNII |
3R2D6N19T5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7675-82-3
Created by
admin on Sat Dec 16 02:06:53 GMT 2023 , Edited by admin on Sat Dec 16 02:06:53 GMT 2023
|
PRIMARY | |||
|
3R2D6N19T5
Created by
admin on Sat Dec 16 02:06:53 GMT 2023 , Edited by admin on Sat Dec 16 02:06:53 GMT 2023
|
PRIMARY | |||
|
9926733
Created by
admin on Sat Dec 16 02:06:53 GMT 2023 , Edited by admin on Sat Dec 16 02:06:53 GMT 2023
|
PRIMARY | |||
|
1010241
Created by
admin on Sat Dec 16 02:06:53 GMT 2023 , Edited by admin on Sat Dec 16 02:06:53 GMT 2023
|
PRIMARY | RxNorm |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |